Introduction
Corona virus is a positive sense single standard RNA viruses and these viruses are known to cause infections mainly in animals and a part to humans also.1 In December 2019, World Health Organization was informed from China the occurrence of a cluster of cases of pneumonia of unknown etiology. It was named as the novel Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2, and it was found to be closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV). The patients infected with the COVID-19 have been known to suffering with sudden onset of fever, myalgia, cough, dyspnea along with atypical pneumonia.2 The clinical picture was supported by the radiological evidence of the ground glass opacities of the lungs. WHO has declared the COVID-19 as a pandemic and the case fatality rate ranges from 1% to 12%.3 The major concern of the COVID-19 is the spread through person to person contact and several countries in more than 200 are implementing the containments strategies as advised by the WHO to prevent the spread of the viruses among individuals.5Scientists in various countries are working out and clinical trials are underway for the development of effective vaccines for COVID-19.
Early detection of the SARS-CoV-2 in symptomatic and asymptomatic patients is one of the best way to prevent the spread of this virus. Several countries are evaluating the detection of antigen and antibody, but the major problem in establishing the effective assay is the cross reactivity with the SARS-CoV.4 There is a need of a novel technique which has an ability to detect the etiology of the COVID-19 with high sensitivity and specificity for early testing, diagnosing, and ability to detect both symptomatic and asymptomatic carriers of the virus. Worldwide recent studies pointed out that the most reliable diagnostic test for the detection of the COVID-19 is the reverse transcription-PCR (RT-PCR). The access of the complete genome has lead to the development of RT-PCR assay targeting the RNA-dependent RNA polymerase (RdRp), envelope (E), and nucleocapsid (N) genes of SARS-CoV-2.5
In this present pilot study we evaluated the AllplexTM 2019-CoV assay RT-PCR for the detection of the SARS-CoV-2 in symptomatic patients visited in our hospital.
Materials and Methods
Clinical specimen
The pilot study has been conducted from the department of Microbiology, Kurnool Medical College, Andhra Pradesh. The pilot study was conducted for the month of June 2020, the nasopharyngeal swabs were collected from the patients showing clinical symptoms. A total of 49,033 were collected comprising 29, 685 at the individual level and 19,348 pooled samples.
Nucleic acid extraction for SARS-CoV-2
RNA extraction was performed from the clinical specimens using HiPurA® Viral RNA Purification Kit (Hi media, Netherlands). After the elution, the RNA was stored at -20ᵒC till further analysis using RT-PCR.
RT-PCR
Real-time RT-PCR assay for SARS-CoV-2 RNA detection was performed using AllplexTM 2019-nCoV Assay (Seegene, Seoul, Republic of Korea), according the instructions given and RT-PCR was performed in the thermocycler RT-PCR Biorad cfx96 (----). The thermal profile included 1st Hold temperature of 50ᵒC for 20 min, 2nd Hold temperature of 95ᵒC for 15 min and PCR 45 cycle which includes 94ᵒC for 15 sec and 58ᵒC for 30 sec. Fluorescence is detected at 58°C. The flurophore used includes FAM for E gene, HEX for the internal control, Cal Red 610 for RdRp gene and Quasar 670 for N gene respectively. The data was analysed through application of the Seegene Viewer software, Applied Biosystems™ 7500.
Results
In a 1 month June 2020, a total of 49,033 were collected comprising 29,685 at the individual level and 19,348 pooled nasopharyngeal swabs received from all over the Kurnool District of Andhra Pradesh were evaluated for the presence of COVID-19 agent through application of RT-PCR. A total of 1364 cases (2.7%) were detected positive for the SARS-CoV-2 RNA and the remaining samples of total 47,441 were negative for the above mentioned virus. All the 3 genes were detected in the assay. The persons positive were informed and these patients were subjected to immediate quarantine to prevent the spread of the virus.
Table 1
Total number of people tested |
Total number of individual samples |
Total number of pooled samples |
Total number of positives |
Total number of negatives |
49,033 |
26,685 |
19,348 |
1,364 |
47,441 |
.
Discussion
The COVID-19 has affected the several countries and WHO has declared it as a pandemic affecting the persons irrespective of caste, creed, rich or poor. Several countries are in following the instructions and guidance provided by the WHO to contain the spread of the COVID-19 virus. Early detection of virus through application of RT-PCR helps to prevent the spread of the COVID-19 at the earliest. In the present pilot study we evaluated the presence of this virus in larger population in our district, and was evaluated using AllplexTM 2019-nCoV Assay (Seegene, Seoul, Republic of Korea). The advantage of this kit, that it has an ability to identifies 3 different target genes (E, RdRP and N genes) simultaneously in a single reaction tube which allows for highly accurate results. In the present study we found 2.7% of cases were positive for COVID-19. Similarly a study conducted by Drew and co-workers using the using AllplexTM 2019-nCoV Assay found the 17% were positive for 3 genes, 4 (1.4%) samples were positive for 2 genes (all N gene and RdRP gene), 8 (3%) samples were positive for 1 gene (all N gene only).6 In another study through application AllplexTM 2019-nCoV Assay found no cross reactivity and found reliable for the detection of COVID-19.7
We conclude the present pilot study analysis of detection of COVID-19 using AllplexTM 2019-nCoV Assay is very useful in detecting the suspected COVID-19 cases at the earliest and helps in preventing the spread of the infection. Further study with larger sample size is warranted.